6 - 12 Feb 2012

Analysis: Anticoagulants in the PBS spotlight

Professor Lloyd Sansom's review of anticoagulant therapies - better known as the Pradaxa review - will soon get underway with submissions due to close this month. What does it presage for the future operation of the PBS? » more

News

AZ staff await job cut news
	After days of speculation internationally, AstraZeneca has announced it will axe 7,300 jobs across its business as part of a restructuring plan it says will save US$1.6 billion a year by the end of 2014. It remains unclear whether Australian operations will be affected » full report

GSK expands local manufacturing
	GlaxoSmithKline will plough $60 million into the expansion of its Boronia site in Victoria, creating 58 new highly-skilled jobs by 2017 » full report

Sandoz steers clear of Crestor fight
	Sandoz has agreed not to launch a generic version of Crestor in Australia pending decisions on Apotex, Watson and Actavis injunctions currently before the courts, according to AstraZeneca » full report

Fall in per capita PBS spend
	Per capita spending under the PBS dropped by $11 a head between 2009-10 and 2010-11, according to a new report from the Productivity Commission » full report

Sanofi's Lyxumia on approval track
	Despite the company refusing to confirm an Australian filing, all indications are that Sanofi's GLP-1 agonist for type 2 diabetes, Lyxumia could soon appear the on the Therapeutic Goods Register » full report

Party donations top $400K
	The Australian Labor Party and the Liberal Party have both reported 22% increases in receipts from the pharmaceutical industry in the Electoral Commission's annual report on financial disclosure returns for the 2010-2011 financial year » full report

Latest ARTG registrations
	Just bought by Watson and embroiled in legal wrangles with AstraZeneca, Ascent Pharma has now registered numerous potential Crestor competitors » full report

FREE content

Comment

Pharma's two faces on display

Today's Pharma in Focus shows two faces of pharma. One we've unfortunately grown used to over recent years, the regular announcement of job cuts, but the other is more encouraging » full report

Missed Anything? Catch Up Here

Instant Update - Tuesday 31 Jan to Friday 3 Feb
Market Review - Oral antidiabetics in a time of change
Drug Tracker - Review of PBAC trends from 2011
Special Report - 2012: When PBS reform really starts to bite
Special Feature - Top ten stories of 2011

FREE content

Bionomics presents kidney cancer hope - Potential new treatment paradigm - » full report
Apixaban benefits stroke patients - Effective in secondary and primary prevention - » full report